Recent research from scientists at Northwestern University has brought to light serious concerns about the safety of two widely prescribed drugs for managing type 2 diabetes.
These drugs, sulfonylureas and basal insulin, have been linked to an increased risk of heart-related complications, including heart attacks, strokes, heart failure, and even amputations in diabetes patients.
The Role of Sulfonylureas and Basal Insulin
When it comes to treating type 2 diabetes, metformin is usually the first drug doctors prescribe. It’s well-known and widely used because of its effectiveness and safety.
However, not all patients respond well to metformin, and some can’t tolerate it at all. In these cases, doctors often turn to secondary medications like sulfonylureas and basal insulin to help manage blood sugar levels.
The study conducted by Northwestern University is the first of its kind to compare the effects of six major second-line diabetes drugs on heart health in patients who need additional treatment beyond metformin.
What the Study Found
The study’s findings are concerning. Patients who were taking sulfonylureas were found to be 36 percent more likely to suffer from cardiovascular problems such as heart attacks, strokes, heart failure, or amputations, compared to those taking a newer class of diabetes drugs known as DPP-4 inhibitors.
For patients on basal insulin, the risk was even more alarming, with a twofold increase in the likelihood of experiencing these serious heart-related issues.
These results are particularly significant because sulfonylureas and basal insulin are prescribed to about 60 percent of patients who need a second-line diabetes medication.
Given that approximately 30 million Americans have diabetes, this means that a large number of people could be at risk of serious cardiovascular harm from these medications.
Considering Safer Alternatives
Given the potential risks, the research team suggests that doctors should consider prescribing newer types of diabetes medications after metformin, such as GLP-1 agonists (like liraglutide), SGLT-2 inhibitors (like empagliflozin), or DPP-4 inhibitors (like sitagliptin).
These newer drugs have shown better safety records when it comes to heart health.
One reason sulfonylureas and basal insulin remain popular despite the risks is their lower cost. They are cheaper than the newer alternatives, and this often plays a significant role in treatment decisions.
However, the study emphasizes the importance of considering the potential cardiovascular risks alongside the financial costs.
Real-World Evidence and Patient Safety
The study’s findings are based on real-world data from a large group of 132,737 patients with type 2 diabetes who started on second-line treatment. This approach provides valuable insights that complement previous studies, which often focused on comparing a single drug to a placebo.
The research highlights the need for patients to be fully informed about the possible heart-related risks associated with their diabetes medications. It also calls for a change in how type 2 diabetes is treated, with a stronger focus on protecting the cardiovascular health of patients.
The study, led by Dr. Matthew O’Brien and published in JAMA Network Open, is likely to prompt doctors and patients alike to rethink their approach to diabetes treatment.
It underscores the need for a careful balance between managing blood sugar levels and ensuring that the treatment itself doesn’t introduce new health risks.
If you care about diabetes, please read studies about a cure for type 2 diabetes, and these vegetables could protect against kidney damage in diabetes.
For more information about diabetes, please see recent studies about bone drug that could lower risk of type 2 diabetes, and results showing eating more eggs linked to higher risk of type 2 diabetes.
Copyright © 2024 Knowridge Science Report. All rights reserved.
